During the past decade, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo conducted 77 clinical trials. In the 10-year time frame, 77 clinical trials started and 18 clinical trials were completed, i.e. on average, 23.4% percent of trials that started reached the finish line to date. In the past 5 years, 43 clinical trials started and 13 clinical trials were completed. i.e. 30.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo" #1 sponsor was "University of Sao Paulo" with 32 trials, followed by "Janssen Research & Development, LLC" with 8 trials sponsored, "Eli Lilly and Company" with 6 trials sponsored, "Hoffmann-La Roche" with 6 trials sponsored and "Boehringer Ingelheim" with 6 trials sponsored. Other sponsors include 50 different institutions and companies that sponsored additional 41 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo" #1 collaborator was "Fundação de Amparo à Pesquisa do Estado de São Paulo" with 11 trials as a collaborator, "Ministry of Health, Brazil" with 5 trials as a collaborator, "Conselho Nacional de Desenvolvimento Científico e Tecnológico" with 3 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator and "Basilea Pharmaceutica International Ltd" with 2 trials as a collaborator. Other collaborators include 42 different institutions and companies that were collaborators in the rest 50 trials.

According to Clinical.Site data, the most researched conditions in "Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo" are "Diabetic Macular Edema" (3 trials), "Diabetic Retinopathy" (3 trials), "Metastatic Breast Cancer" (3 trials), "Obesity" (3 trials) and "Sickle Cell Disease" (3 trials). Many other conditions were trialed in "Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo" in a lesser frequency.

Most popular intervention types in "Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo" are "Drug" (70 trials), "Other" (21 trials), "Biological" (15 trials), "Device" (8 trials) and "Procedure" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (26 trials), "Ad26.COV2.S" (3 trials), "Mitapivat" (3 trials), "Abemaciclib" (2 trials) and "Bevacizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo" are 97 trials for "All" genders, 11 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo". undefined are not yet recruiting, 22 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 51 completed trials in Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, 12 "Phase 1" clinical trials were conducted, 25 "Phase 2" clinical trials and 53 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 22 trials that are defined as “Not Applicable".